Evidence map›Paper›PMID 39859392›Full record

ArticleInternational journal of molecular sciences2025

Clinical and Genomic Features of Androgen Indifferent Prostate Cancer.

Jack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, Adanma Ayanambakkam, Michelle L Churchman, Laura S Graham, George Daniel Grass, Sumati Gupta, Sean Q Kern, Jennifer King and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jack MasurDivision of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0009-0008-5853-9697
Aakrosh RatanCenter for Public Health Genomics, University of Virginia, Charlottesville, VA 22903, USA.
Krzysztof WierbilowiczDepartment of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.ORCID 0000-0002-6896-7846
Adanma AyanambakkamStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0001-8070-7927
Michelle L ChurchmanAster Insights, Hudson, FL 34667, USA.
Laura S GrahamDepartment of Medicine, Division of Medical Oncology, University of Colorado Cancer Center Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0003-4371-572X
George Daniel GrassH. Lee Moffitt Cancer Center, Department of Radiation Oncology, Tampa, FL 33612, USA.
Sumati GuptaHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84103, USA.ORCID 0000-0001-6271-0831
Sean Q KernMurtha Cancer Center, Uniformed Services University, Bethesda, MD 20814, USA.ORCID 0000-0001-8753-5726
Jennifer KingDepartment of Medicine, Division of Hematology and Medical Oncology, Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA.
Zin MyintDivision of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY 40546, USA.ORCID 0000-0002-3479-4203
Robert J RounbehlerAster Insights, Hudson, FL 34667, USA.
Bodour SalhiaNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Eric A SingerDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Yousef ZakhariaHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-9480-2626
Bryce M PaschalDepartment of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Paul V ViscuseDivision of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0003-0834-8688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen-indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse, and AIPC remains a poorly understood malignancy. Utilizing the Oncology Research Information Exchange Network (ORIEN) database, we enriched for tumors with features of AIPC using previously described characteristics. Our AIPC cohort included three subgroups: aggressive variant prostate cancer (AVPC), neuroendocrine PC (NEPC), and double-negative PC (DNPC). Of 1496 total PC patients available for analysis, we identified 323 (22%) as MCRPC. Of those, 39 (12%) met AIPC criteria (17 AVPC, 13 NEPC, 9 DNPC) and 284 (88%) were non-AIPC. Forty-three percent of AIPC patients had de novo metastatic disease vs. 15% for non-AIPC (

Indexed as

AndrogensProstatic NeoplasmsAgedBiomarkers, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGenomicsHumansMaleMicrosatellite InstabilityMiddle AgedMutationAndrogensBiomarkers, Tumorandrogen-indifferent prostate cancerbiomarkersgenomicsmolecular biologyprostate cancertherapeutic targets

Identifiers

PMID39859392
PMCPMC11765751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.